ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS

• Formulation Considerations For Pediatric Populations

  By partnering with a CDMO with experience in pediatric formulation, pharmaceutical companies can increase acceptability of their drugs among pediatric patients.

• 4 Factors Affecting Solubility Of Drugs

  Improper drug solubility can lead to suboptimal drug delivery and absorption, resulting in ineffective drug efficacy and side effects, so solubility must be evaluated in the early stages of drug discovery.

• Making The Right Choice For Multiparticulate Modified Release Dosage Forms

  Wurster processing is a versatile pharmaceutical development and manufacturing technique for multiparticulates in modified release dosage forms. Understand if it's the right method for your modified-release project.

• Liquid Capsule Manufacturing: What To Know

  Capsules surround a drug in an unflavored, solid barrier enclosure. This article focuses on liquid capsule manufacturing and its advantages.

• Overcoming Limitations To Achieve Uniform Dosing

  An immediate need for lower dose capsules in the clinic posed several challenges in blend formulation with very tight timelines for delivery.

• Reducing Lead Time & Optimizing Costs

  Explore how the use of this component platform produces significant savings, reduces elastomer SKU complexity, and increases speed to market.

• Closing The Duration Gap In FDA-Approved Long-Acting Contraceptives

  A gap exists between three months and three years in FDA-approved long-acting contraceptives (LACs). A microsphere formulation enables sustained release over a six to twelve-month period.

• Compliance Considerations For Emergency-Use Delivery Systems

  Because auto-injectors are typically the delivery device of choice for emergency medications, they come with increased scrutiny from regulatory bodies regarding their safety and effectiveness.

• Best Practices For Ensuring Quality In Biologic Products

  New biologic therapies have new challenges in their packaging and delivery systems because of their complexities, higher stability risks, and larger sizes. 

• The Future Of CDMOs: Aseptic Filling Solutions For Growth And Innovation

  The rapid rise of highly targeted cell and gene treatments requiring small batch production necessitates a new path forward for biologics manufacturing and directly impacts the CMO/CDMO landscape.